NASDAQ:VIRX

Viracta Therapeutics (VIRX) Stock Forecast, Price & News

$1.52

+0.02 (+1.33%)

(As of 06/9/2023 ET)

Compare

Today's Range: $1.48
▼
$1.59
50-Day Range: $0.89
▼
$2.13
52-Week Range: $0.88
▼
$5.75

Volume: 112,321 shs
Average Volume: 505,077 shs
Market Capitalization: $58.47 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.00

Viracta Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,150.0% Upside
$19.00 Price Target
Short Interest: Healthy
2.33% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$5,162 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.25) to ($1.12) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.39 out of 5 stars

Medical Sector

420th out of 988 stocks

Pharmaceutical Preparations Industry

194th out of 481 stocks

3.5

Analyst's Opinion

Consensus Rating
Viracta Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $19.00, Viracta Therapeutics has a forecasted upside of 1,150.0% from its current price of $1.52.
Amount of Analyst Coverage
Viracta Therapeutics has only been the subject of 3 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
2.33% of the float of Viracta Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Viracta Therapeutics has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Viracta Therapeutics has recently decreased by 2.24%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Viracta Therapeutics does not currently pay a dividend.
Dividend Growth
Viracta Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VIRX.

3.3

News and Social Media Coverage

News Sentiment
Viracta Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Viracta Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 14 people have searched for VIRX on MarketBeat in the last 30 days. This is a decrease of -30% compared to the previous 30 days.
MarketBeat Follows
7 people have added Viracta Therapeutics to their MarketBeat watchlist in the last 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Viracta Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,162.00 in company stock.
Percentage Held by Insiders
27.63% of the stock of Viracta Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 32.35% of the stock of Viracta Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Viracta Therapeutics are expected to grow in the coming year, from ($1.25) to ($1.12) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Viracta Therapeutics is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Viracta Therapeutics is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Viracta Therapeutics has a P/B Ratio of 1.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Viracta Therapeutics (NASDAQ:VIRX) Stock

Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas. The company was founded on February 10, 1998 and is headquartered in Cardiff, CA.

Receive VIRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viracta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VIRX Stock News Headlines

May 14, 2023 | americanbankingnews.com

Analysts Offer Predictions for Viracta Therapeutics, Inc.'s Q2 2023 Earnings (NASDAQ:VIRX)

May 11, 2023 | msn.com

HC Wainwright & Co. Maintains Viracta Therapeutics (VIRX) Buy Recommendation

June 10, 2023 | Altimetry (Ad)

Surprising "Twist" Hands Biden Landslide Re-election?

This could make it harder than ever to hang onto the money you make as Progressives gain power, and America slides further towards Socialism.

May 11, 2023 | finance.yahoo.com

Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

May 11, 2023 | americanbankingnews.com

Viracta Therapeutics (NASDAQ:VIRX) Price Target Lowered to $33.00 at HC Wainwright

May 10, 2023 | markets.businessinsider.com

Analyst Ratings for Viracta Therapeutics

May 9, 2023 | msn.com

RBC Capital Maintains Viracta Therapeutics (VIRX) Outperform Recommendation

May 9, 2023 | finanznachrichten.de

Viracta Therapeutics, Inc.: Viracta Therapeutics Reports First Quarter 2023 Financial Results and Provides Clinical Program Updates

June 10, 2023 | Altimetry (Ad)

Surprising "Twist" Hands Biden Landslide Re-election?

This could make it harder than ever to hang onto the money you make as Progressives gain power, and America slides further towards Socialism.

May 8, 2023 | finance.yahoo.com

Viracta Therapeutics Reports First Quarter 2023 Financial Results and Provides Clinical Program Updates

May 4, 2023 | seekingalpha.com

Viracta Therapeutics CMO Lisa Rojkjaer, M.D to depart

May 2, 2023 | finance.yahoo.com

Viracta Therapeutics Announces Departure of Chief Medical Officer

April 19, 2023 | finance.yahoo.com

Viracta Therapeutics to Present at the Stifel 2023 Targeted Oncology Days

April 18, 2023 | americanbankingnews.com

Short Interest in Viracta Therapeutics, Inc. (NASDAQ:VIRX) Declines By 19.5%

April 13, 2023 | americanbankingnews.com

Comparing Altamira Therapeutics (NASDAQ:CYTO) & Viracta Therapeutics (NASDAQ:VIRX)

March 30, 2023 | americanbankingnews.com

Short Interest in Viracta Therapeutics, Inc. (NASDAQ:VIRX) Grows By 51.7%

March 29, 2023 | americanbankingnews.com

Analysts Issue Forecasts for Viracta Therapeutics, Inc.'s Q1 2023 Earnings (NASDAQ:VIRX)

March 29, 2023 | americanbankingnews.com

Viracta Therapeutics (NASDAQ:VIRX) PT Raised to $16.00 at Oppenheimer

March 14, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Oncternal Therapeutics (ONCT) and Viracta Therapeutics (VIRX)

March 13, 2023 | finance.yahoo.com

Viracta Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

March 8, 2023 | finance.yahoo.com

Viracta Therapeutics to Present at the 33rd Annual Oppenheimer Healthcare Conference

February 28, 2023 | markets.businessinsider.com

Viracta Therapeutics (VIRX) Gets a Buy from RBC Capital

February 7, 2023 | finance.yahoo.com

Viracta Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference

January 19, 2023 | finance.yahoo.com

Viracta Therapeutics Announces Orphan Drug Designation Granted by the European Commission to Nana-val for the Treatment of Diffuse Large B-cell Lymphoma

January 8, 2023 | tmcnet.com

Viracta Therapeutics Announces First Clinical Response in Epstein-…

January 8, 2023 | finance.yahoo.com

Viracta Therapeutics Announces First Clinical Response in Epstein-Barr Virus-Positive (EBV+) Solid Tumor Setting and Outlines Key 2023 Clinical Objectives

November 30, 2022 | tmcnet.com

Viracta Therapeutics Announces Preliminary Dose-Ranging Data from

See More Headlines

VIRX Price History

30 days | 90 days | 365 days | Advanced Chart

VIRX Company Calendar

Last Earnings: 3/13/2023
Today: 6/09/2023
Next Earnings (Estimated): 8/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:VIRX
CUSIP: N/A
CIK: 1061027
Web: www.viracta.com
Phone: (858) 400-8470
Fax: 650-266-3501
Employees: 24
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $19.00
High Stock Price Forecast: $33.00
Low Stock Price Forecast: $8.00
Forecasted Upside/Downside: +426.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.34)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-49,200,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -86.49%
Return on Assets: -57.61%

Debt

Debt-to-Equity Ratio: 0.50
Current Ratio: 7.16
Quick Ratio: 7.16

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.46 per share
Price / Book: 1.04

Miscellaneous

Outstanding Shares: 38,470,000
Free Float: 27,839,000
Market Cap: $58.47 million
Optionable: Not Optionable
Beta: 1.22

Key Executives

Mark A. Rothera
President, Chief Executive Officer & Director

Daniel R. Chevallard
Secretary, Chief Operating & Financial Officer

Ayman El-Guindy
Chief Scientific Officer

Donald Strickland
VP-Clinical Development & Medical Director

Patric Nelson
Senior VP-Business Development & Strategy

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VIRX Stock - Frequently Asked Questions

Should I buy or sell Viracta Therapeutics stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viracta Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VIRX shares.
View VIRX analyst ratings or view top-rated stocks.
What is Viracta Therapeutics' stock price forecast for 2023?: 3 Wall Street analysts have issued 12-month price targets for Viracta Therapeutics' shares. Their VIRX share price forecasts range from $8.00 to $33.00. On average, they predict the company's stock price to reach $19.00 in the next twelve months. This suggests a possible upside of 1,150.0% from the stock's current price.
View analysts price targets for VIRX or view top-rated stocks among Wall Street analysts.
How have VIRX shares performed in 2023?: Viracta Therapeutics' stock was trading at $1.46 at the beginning of 2023. Since then, VIRX stock has increased by 4.1% and is now trading at $1.52.
View the best growth stocks for 2023 here.
When is Viracta Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our VIRX earnings forecast.
How were Viracta Therapeutics' earnings last quarter?: Viracta Therapeutics, Inc. (NASDAQ:VIRX) released its quarterly earnings results on Monday, March, 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.13.

What is Viracta Therapeutics' stock symbol?: Viracta Therapeutics trades on the NASDAQ under the ticker symbol "VIRX."
Who are Viracta Therapeutics' major shareholders?: Viracta Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Rubric Capital Management LP (3.87%), MAI Capital Management (0.99%), Renaissance Technologies LLC (0.33%), Dimensional Fund Advisors LP (0.32%), Jane Street Group LLC (0.14%) and Trust Co. of Toledo NA OH (0.07%). Insiders that own company stock include Daniel R Chevallard, Ivor Royston and Lisa Rojkjaer.
View institutional ownership trends.
How do I buy shares of Viracta Therapeutics?: Shares of VIRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Viracta Therapeutics' stock price today?: One share of VIRX stock can currently be purchased for approximately $1.52.
How much money does Viracta Therapeutics make?: Viracta Therapeutics (NASDAQ:VIRX) has a market capitalization of $58.47 million. The company earns $-49,200,000.00 in net income (profit) each year or ($1.34) on an earnings per share basis.
How can I contact Viracta Therapeutics?: Viracta Therapeutics' mailing address is 2533 S. COAST HWY. 101 SUITE 210, CARDIFF CA, 92007. The official website for the company is www.viracta.com. The company can be reached via phone at (858) 400-8470, via email at bjerkholt@sunesis.com, or via fax at 650-266-3501.

This page (NASDAQ:VIRX) was last updated on 6/10/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial